← Savara Inc (SVRA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Savara Inc (SVRA)
Pharmaceutical Preparations · market cap $1.0B · as of 2026-07-20
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Savara Inc (SVRA) is a clinical-stage pulmonary-focused pharmaceutical company with zero revenue and a $1.13B market cap. Its two lead programs are molgramostim (inhaled GM-CSF) in Phase 3 for autoimmune pulmonary alveolar proteinosis (aPAP) and vancomycin inhalation powder in Phase 3 for MRSA lung infections. The company reports critically thin cash of $38.8M against an estimated 3.5-month runway, making near-term financing a near-certainty.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Inhaled molgramostim | Phase 2 | Mycobacterium Infections, Nontuberculous |
| Molgramostim | Phase 3 | Autoimmune Pulmonary Alveolar Proteinosis |
Price & technical context
3-month
-18.8%
6-month
-9.5%
12-month
+41.5%
52-wk range
$3.37–$6.94
vs 50-day MA
-6.5%
vs 200-day MA
-8.7%
Realized vol
53.2%
Max drawdown
-58.2%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SVRA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.